Providing improved immunoglobulin sequences by mutating CDR and/or FR positions

Details for Australian Patent Application No. 2008270274 (hide)

Owner Ablynx N.V.

Inventors Kolkman, Joost Alexander

Agent Shelston IP

Pub. Number AU-B-2008270274

PCT Pub. Number WO2009/004065

Priority 60/958,164 03.07.07 US

Filing date 3 July 2008

Wipo publication date 8 January 2009

Acceptance publication date 28 June 2012

International Classifications

C07K 16/28 Immunoglobulins, e.g. monoclonal or polyclonal antibodies

C12Q 1/68 Measuring or testing processes involving enzymes or micro-organisms - involving nucleic acids

Event Publications

28 January 2010 PCT application entered the National Phase

  PCT publication WO2009/004065 Priority application(s): WO2009/004065

28 June 2012 Application Accepted

  Published as AU-B-2008270274

25 October 2012 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2008270280-Use of piperine and derivatives thereof for the therapy of neurological conditions

2008270269-Novel triazine compounds for treatment of cancer